38 Result(s)

Article

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

Purpose To investigate the toxicity profile, activity, pharmacokinetics, and pharmacodynamics of pemetrexed in leukemia. Patients and Methods Patients with refractory or relapsed acute leukemia were eligible. A p...

Isam Abdel-Karim, William K. Plunkett Jr, Susan O’Brien… in Investigational New Drugs (2011)

Article

Survival Advantage in CLL with Frontline FCR Therapy

Susan O’Brien in Current Hematologic Malignancy Reports (2011)

Article

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable progno...

Deborah A. Thomas, Susan O’Brien, Stefan Faderl… in Current Hematologic Malignancy Reports (2011)

Chapter

Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy

The advent of monoclonal antibody therapy heralded a new era in oncology. In 1997, rituximab became the first monoclonal antibody for the treatment of cancer following its approval for patients with B-cell non...

André Goy, Susan O’Brien in Principles and Practice of Cancer Infectious Diseases (2011)

Chapter

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Significant advances have been made with respect to the treatment of Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) since the discovery of the selective ABL tyrosine kinase...

Deborah A. Thomas, Susan O’Brien, Stefan Faderl… in Adult Acute Lymphocytic Leukemia (2011)

Article

Novel therapies for relapsed acute lymphoblastic leukemia

The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monoth...

Amber Fullmer, Susan O’Brien, Hagop Kantarjian… in Current Hematologic Malignancy Reports (2009)

Article

Targeted therapy for chronic lymphocytic leukemia

The introduction of targeted agents such as the monoclonal antibodies rituximab (anti-CD20) and alemtuzumab (anti-CD52) has brought about a remarkable change in the therapy of chronic lymphocytic leukemia (CLL...

Alfonso Quintás-Cardama, Susan O’Brien in Targeted Oncology (2009)

Article

Successful treatment of cancer-associated retinopathy with alemtuzumab

We herein report a patient with cancer-associated retinopathy who experienced multiple bouts of paraneoplastic retinopathy and optic neuropathy but responded to treatments with alemtuzumab and was able to main...

Ladan Espandar, Susan O’Brien, Charles Thirkill… in Journal of Neuro-Oncology (2007)

Article

The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents

Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The disease is characterized by the presence of the Philadelphia chromosome, which arises following a balanced transl...

Elias Jabbour, Jorge Cortes, Francis Giles, Susan O’Brien… in Targeted Oncology (2006)

Article

Immune defects in patients with chronic lymphocytic leukemia

Over the past decade, the introduction of nucleoside analogs and monoclonal antibodies into the treatment of patients with chronic lymphocytic leukemia (CLL) has resulted in higher rates and longer duration of...

Farhad Ravandi, Susan O’Brien in Cancer Immunology, Immunotherapy (2006)

Article

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Its role as a component of post-remission thera...

Apostolia M. Tsimberidou, Elihu Estey… in Cancer Chemotherapy and Pharmacology (2003)

Article

Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies

Abstract

Apostolia-Maria Tsimberidou, Deborah Thomas… in Cancer Chemotherapy and Pharmacology (2002)

Article

A Guide to the Use of Interferon-Alpha in the Management of Chronic Myelogenous Leukaemia

Interferon-alpha (IFNα) can induce major cytogenetic responses in 30 to 40% of patients with chronic myelogenous leukaemia (CML) and up to 50% when combined with cytarabine (ara-C). These responses translate i...

Dr Jorge Cortes, Susan O’Brien in BioDrugs (2000)

Article

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

The topoisomerase I inhibitor topotecan has shown activity in acute myeloid leukemia (AML) and myelodysplastic syndromes. The present study was designed to assess whether topotecan with cytosine arabinoside (a...

Norbert Vey, Hagop Kantarjian, Miloslav Beran, Susan O'Brien… in Investigational New Drugs (1999)

Article

Phase I study of liposomal daunorubicin in patients with acute leukemia

The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing to...

Jorge Cortes, Susan O'Brien, Elihu Estey, Francis Giles… in Investigational New Drugs (1999)

Article

Clinical Experience with Fludarabine in Leukaemia

Fludarabine (Fludara®) is a new purine analogue that was first entered into clinical trials in 1982. Results of initial studies with high dosages (> 96 mg/m²/day for 5 to 7 days) of fludarabine in acute leukaemia...

Prof. Michael J. Keating, Eli Estey, Susan O’Brien, Hagop Kantarjian… in Drugs (1994)